Dumanskyi Yu. V., Palii M. I.

CLINICAL COURSE OF PROSTATE CANCER AND FACTORS THAT DETERMINE IT

---

Show/Download

About the author:

Dumanskyi Yu. V., Palii M. I.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

Prostate cancer (PC) remains a serious medical problem nowadays. Unsolved issues include early diagnosis of PC and choosing the right treatment tactics. Purpose: to assess the level of markers of the tumour process in patients with prostate cancer and determine their influence on the course of the disease. A retrospective analysis of 1,587 patients with PC who were in the National Cancer Institute (Kyiv) was conducted. The indicators of CT and MRI results, instrumental and morphological examination methods, and the level of PSA, TS, LT, ISF1, APP, AP and GH markers were analyzed. A prostate gland biopsy was performed with a pathomorphological examination of the tumour tissue. Results: in 46.2% of patients, an increase in the level of TS in blood serum was established in all patients - PSA, in 65.1% - ISF1, in 99.5% - APP, in 99% - AP and in 76.4% - GH. In the case of PC, the integrated state of markers of the tumour process was influenced by the indicators of pT (WR=2.35; p<0.001), pN (WR=3.30; p<0.001), M (WR=4.95; p<0.001), prevalence (TNM) (WR=2.35; p<0.001) and primary tumour size (according to ultrasound) (WR=4.22; p<0.001), GS (WR=1.92; p<0.001), tumour localization in the peripheral zone (WR=3.13; p<0.001), STT (WR=3.50; p<0.001), GDT (WR=1.75; p<0.001), the presence of metastases in the lymph nodes (WR=2 .38; p<0.001), distant organs (WR=2.33; p<0.001) and bones of the skeleton (WR=2.42; p<0.001), as well as the presence of macrohematuria (WR=2.85; p=0.008 ), comorbid renal clear cell carcinoma (WR=2.69; p=0.011) and breast adenocarcinoma (WR=2.50; p=0.001). Conclusions: effective markers of the tumour process, AP and APP activity parameters for the PC screening have prognostic significance and can be criteria for the effectiveness of treatment.

Tags:

Bibliography:

1. Carlsson SV, Vickers AJ. Screening for Prostate Cancer. Med Clin North Am. 2020;104(6):1051-1062. DOI: 10.1016/j.mcna.2020.08.007.
2. Anker MS, Holcomb R, Muscaritoli M, von Haehling S, Haverkamp W, Jatoi A, et al. Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review. J Cachexia Sarcopenia Muscle. 2019;10(1):22-34. DOI: 10.1002/jcsm.12402.
3. Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, et al. ERSPC investigators. A 16-yr follow-up of the european randomized study of screening for prostate cancer. Eur Urol. 2019;76(1):43-51. DOI: 10.1016/j.eururo.2019.02.009.
4. Xu H, Wang F, Xu H, Wang F, Li H, Ji J, et al. Prostatic Acid Phosphatase (PAP) Predicts Prostate Cancer Progress in a Population-Based Study: The Renewal of PAP? Dis Markers. 2019;2019:7090545. DOI: 10.1155/2019/ 7090545.
5. Alpert E, Akhavan A, Gruzman A, Hansen WJ, Lehrer-Graiwer J, Hall SC, et al. Multifunctionality of Prostatic Acid Phosphatase in Prostate Cancer Pathogenesis. Biosci Rep. 2021;41(10):BSR20211646. DOI: 10.1042/ BCJ20200944.
6. Shrivastava S, editor. Industrial Applications of Glycoside Hydrolases. Singapore: Springer; 2020. Chapter, Glycosyl Hydrolases: Biochemistry and Applications. p. 85-95. DOI: 10.1007/978-981-15-4767-6_2.
7. Singla N, Ghandour RA, Raj GV. Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer. Expert opinion on investigational drugs. 2019;28(3):249-259. DOI: 10.1080/13543784.2019.1570130.
8.  Koh Y, Kawashima A, Ujike T, Nagahara A, Fujita K, Kiuchi H, et al. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer. Anticancer Drugs. 2020;31(10):1099-1102. DOI: 10.1097/ CAD. 0000000000000986.
9. Gao Y, Zhang M, Li X, Zeng P, Wang P, Zhang L. Serum PSA levels in patients with prostate cancer and other 33 different types of diseases. Prog Mol Biol Transl Sci. 2019;162(3):377-90. DOI: 10.1016/bs.pmbts.2018. 12.013.
10. Lang R, Rolny V, Leinenbach A, Karl J, Swiatek-de Lange M, Kobold U, et al. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness. Tumour Biol. 2019;41(3):1010428319827223. DOI: 10.1177/1010428319827223.
11. Di Francesco S, Robuffo I, Caruso M, Giambuzzi G, Ferri D, Militello A. Metabolic alterations, aggressive hormone-naïve prostate cancer and cardiovascular disease: a complex relationship. Medicina. 2019;55(3):0062. DOI: 10.3390/medicina55030062.
12. Gao X, Bao T, Yang H, Lei Y, Jiang X, Huang Y, et al. The association of metabolic syndrome and its components with serum prostatespecific antigen levels. Eur J Cancer Prev. 2019;25(3):0508. DOI: 10.1097/CEJ. 0000000000000508.
13. Pak S, Park SY, Shin TJ, You D, Jeong IG, Hong JH, et al. Association of muscle mass with survival after radical prostatectomy in patients with prostate cancer. J Urol. 2019;202(3):525-532. DOI: 10.1097/JU.00000000 00000249.
14. Jahrreiss V, Laukhtina E, D’Andrea D, Shariat SF. The prognostic value of sarcopenia in patients with prostate cancer: a systematic review. Curr Opin Urol. 2021;31(4):315-323. DOI: 10.1097/MOU.0000000000000885.
15. de Pablos-Rodríguez P, Del Pino-Sedeño T, Infante-Ventura D, de Armas-Castellano A, Ramírez Backhaus M, Ferrer JFL, et al. Prognostic Impact of Sarcopenia in Patients with Advanced Prostate Carcinoma: A Systematic Review. J Clin Med. 2022;12(1):57. DOI: 10.3390/ jcm12010057.
16. Sawaki M, Shien T, Iwata H. TNM classification of malignant tumors (Breast Cancer Study Group). Jpn J Clin Oncol. 2019 Mar 1;49(3):228- 231. DOI: 10.1093/jjco/hyy182.

Publication of the article:

«Bulletin of problems biology and medicine», 2023 Issue 2, 169, 201-210 pages, index UDC 611.637+612.6.054+616.006

DOI:

10.29254/2077-4214-2023-2-169-201-210